



PerkinElmer Announces Latest Expansion of AlphaScreen® Cellular Pathway Analysis Tools

SAN FRANCISCO -PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the release of 11 new AlphaScreen® SureFire® assay kits for the rapid detection of full-length kinase activation in cell lysates. The new kits launched at the 48th annual meeting of The American Society for Cell Biology (ASCB) represent new assays for mapping of cellular kinase pathways involved in many complex diseases such as cancer, cardiovascular, inflammation, and metabolism disorders.

PerkinElmer's AlphaScreen® SureFire® platform is a homogeneous "mix and read" technology that eliminates the cumbersome multiple wash steps typically needed in assays protocols, as well as in Western Blot analysis usually performed when analyzing complex cellular pathways. The AlphaScreen® SureFire® kit greatly simplifies complex protocols, and makes them amenable to automation for high-throughput screening. Moreover, the AlphaScreen® SureFire® kit measures full-length, endogenous protein phosphorylation in a cell based format, offering high sensitivity and precision.

"This latest series of assays for the AlphaScreen® SureFire® platform continues PerkinElmer's ongoing mission to provide researchers with critical tools they need to advance their cell-based assay research for drug discovery," said Richard M. Eglon, Ph.D., president, Bio-discovery, PerkinElmer. "With continued emphasis on kinase-based research and the growing need for new technologies to measure cellular pathway activation, PerkinElmer is taking action to provide solutions for evolving researcher requirements."

With the addition of the 11 new assays, there are now, in total, 39 AlphaScreen® SureFire® kits available, allowing complete characterization of cell kinase signaling. Among the new kits are two that measure direct phosphorylation of cellular receptors: Insulin and IGF-1 receptors.

The latest assay kits include:

- Phospho-ALK (Tyr1586)
- Phospho-ALK (Tyr1604)
- Phospho-Chk-1 (Ser345)
- Phospho-c-Jun (Ser63)
- Phospho-c-Jun (Ser73)
- Phospho-EGF receptor (Tyr1068)
- Phospho-Elk-1 (Ser383)
- Phospho-ErbB2 (Tyr1221/1222)
- Phospho-IGF-1 Receptor (Tyr1135/1136)
- Phospho-Insulin receptor (Tyr1150/1151)
- Phospho-mTOR (Ser2448)

Please visit www.perkinelmer.com/surefire to view the full product listing.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of \$1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through reported revenue of \$1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Effective January 1, 2009, PerkinElmer will begin operating within two businesses-Human Health and Environmental Health. In the interim, PerkinElmer will continue to operate as two business units-Life and Analytical Sciences and Optoelectronics.

SureFire® is a registered trademark of TGR BioSciences Pty Ltd.

Media Contact:
Mario R. Fante
PerkinElmer, Inc.
mario.fante@perkinelmer.com
(781) 663-5602